Among the clinical trials on adjuvant chemotherapy for breast cancer, the results of the Breast International Group (BIG) 2–98 trial11 suggested an association between TILs expression and the efficacy of anthracyclines in HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.